Evidence depth: moderate · High public-data fit
Urology
Where to start
Best-fit Urology paths
Directional, modeled. Your priorities decide. Build a report to make it yours.
Data Highlights
Specialty Insights
Competitiveness context: very competitive - NRMP 2024
- Modeled Paths
- 2
- Top Modeled Ceiling
- $800k - $1.2M+
- Best Lifestyle Path
- General Urology
- Highest Equity Upside
- General Urology
Public data · CMS Medicare Part B
What this specialty actually bills Medicare
- Aggregate allowed amount
- $1.5B
- Medicare Part B, not income
- Providers in panel
- 14,935
- NPPES individual NPIs
- NPI → Medicare join
- 59%
- billed Medicare in the year
- Open Payments physicians
- 9,554
- transfers of value, not income
Medicare allowed-$ by subspecialty sector (public CMS data)
Top procedures by Medicare allowed-$ (public CMS data)
- 52000 · Diagnostic exam of bladder and urethra using an endoscope$133M
- 52356 · Crushing of stone of ureter with insertion of stent using an endoscope$23M
- 55700 · Biopsy of prostate gland$19M
- 51728 · Complex measurement of pressure of urine flow in bladder with voiding pressure studies$18M
- 76872 · Ultrasound scan of pelvic region through rectum$15M
Source: CMS Medicare Physician & Other Practitioners (public). This is not W-2 salary, total collections, or take-home income. Aggregate allowed amounts are a partial, biased slice of one payer; sector labels are keyword-inferred from public procedure descriptions and are directional, pending physician review.
Paths
Path families to test
General Urology
High, volume-driven.
External benchmark reference: ~$500k
DoctorCalculator modeled estimate: Owner/Partner Ceiling: $800k - $1.2M+
Urologic Oncology / Robotics
Moderate-High.
External benchmark reference: ~$480k
DoctorCalculator modeled estimate: Ceiling: $550k - $750k
Path Landscape
Compare all 2 paths
3 of 10 dimensions shown. Premium adds ownership / facility upside, geography flexibility, innovation / industry adjacency, and 4 more.
See plansPath battle card
Compare head-to-head
Urology
General Urology
Really about: high-volume outpatient procedures with strong ASC and ancillary upside
validated confidenceUrology
Urologic Oncology / Robotics
Really about: complex robotic surgery, cancer care, and academic prestige
validated confidence- 1. Income ceilingedge → General Urology
- Favorable
A very strong ceiling driven by ancillary services and massive procedure volume.
The reality · The signal · The catch · The verdict
The reality: In-clinic procedures (cystoscopies, TRUS biopsies, vasectomies) are highly efficient and scale beautifully.
The signal: ASC ownership, lithotripsy joint ventures, and in-house pathology labs act as massive multipliers on your base income.
The catch: Mega-groups have optimized billing, contracting, and leverage, pushing the ceiling higher for partners.
The verdict: Provides an excellent, top-tier ceiling for a specialty with a highly controllable lifestyle.
- Mixed
Solid, but often lower than general urology due to case length.
The reality · The signal · The catch · The verdict
The reality: Massive oncologic resections (like robotic cystectomies) take hours and generate poor RVUs per minute.
The signal: Academic salaries are structurally lower than private mega-group compensation.
The catch: If employed by a hospital, you lose the massive ASC and pathology ownership upside.
The verdict: This is a prestige and complexity-driven path, not a pure wealth-maximizer.
- 2. Lifestyle controledge → General Urology
- Favorable
Excellent control; one of the most predictable schedules in surgery.
The reality · The signal · The catch · The verdict
The reality: The practice is overwhelmingly outpatient, elective, and scheduled well in advance.
The signal: You have immense power to control the pace of your clinic and your surgical block time.
The catch: Even major robotic cases (prostatectomies, nephrectomies) are scheduled and rarely emergent.
The verdict: An elite choice for those who want surgical skills but demand a predictable family life.
- Mixed
Lower control than general urology due to case complexity.
The reality · The signal · The catch · The verdict
The reality: Major robotic cancer cases can run late into the evening if complications arise.
The signal: You are tethered to the hospital OR schedule and often fight for robotic block time.
The catch: The patients are sicker and require more complex post-operative management.
The verdict: Significantly less predictable than a pure outpatient clinic practice.
- 3. Sleep / call burdenedge → General Urology
- 4. Ownership / facility upsideedge → General Urology
- 5. Geography flexibilityedge → General Urology
- 6. Innovation / industry adjacencyedge → Urologic Oncology / Robotics
- 7. Training opportunity costedge → General Urology
- 8. Job-market densityedge → General Urology
- 9. Malpractice / litigation pressureedge → General Urology
- 10. Burnout-mismatch riskedge → General Urology
- 11. What people regret
- • Assuming all partners make the same, only to realize the senior partners own the ASC real estate and you are just generating RVUs.
- • The mind-numbing repetition of performing 20 vasectomies and cystoscopies a day.
- • Realizing that doing a 6-hour robotic cystectomy pays less than your partner doing 6 quick laser lithotripsies.
- • Sacrificing your income for academic prestige.
- 12. Best-fit archetypes
- Owner-Operator Physician, Lifestyle-First Clinician
- Prestige-Risk Academic, Procedure-Heavy Wealth Builder
- 13. Poor-fit archetypes
- Prestige-Risk Academic
- Lifestyle-First Clinician
- 14. Questions to ask mentors / fellowships / jobs
- • What is the exact buy-in structure and timeline for the ASC, the lithotripsy joint venture, and the pathology lab?
- • How is the massive volume of clinic procedures (cystoscopies, vasectomies) distributed among junior vs senior partners?
- • Are there private equity restrictions or onerous non-competes in this specific market?
- • Do you have dedicated block time for the robot, or are you fighting general surgery for access?
- • Are you required to take general urology call (kidney stones, catheters) in addition to your oncology cases?
Premium comparison
Who has the edge on the remaining 8 vectors
Premium adds the claim, the signal, and the limitation behind each edge, for both paths. The edge itself is a modeled score comparison, not a measurement.
Evidence & reveals
Urology wealth relies heavily on ancillary ownership (ASC, Litho).
Why · signal · limit · impact
Why: Without ancillaries, the ceiling is capped by simple RVU production.
Signal: Industry data shows mega-groups capture massive ancillary revenue.
Caveat: Do not take a private job without a clear path to ASC/ancillary ownership.
Impact: Push for ownership.
Urologic oncology pays less per hour than general urology.
Why · signal · limit · impact
Why: The RVU system severely punishes long, complex cases.
Signal: Hospital employment strips the ownership upside.
Caveat: Choose this path for the prestige and the medicine, not the money.
Impact:
Scores are relative, directional signals, not dollars and never a salary claim. Each carries its own why, supporting signal, limitation, and decision impact, and the confidence badge shows how validated each path is.
Field notes
- Urology is highly consolidated in many markets (mega-groups), which provides strong ancillary income but makes starting a solo practice very difficult.
Common regret patterns
- Joining a mega-group and realizing the path to partnership is 5 years long and heavily diluted by private equity.
- Getting stuck doing endless cystoscopies when you wanted to do major robotics.
Questions to ask
- Where did recent graduates land, and at what real compensation model?
- What's the realistic path to ownership or production upside?
Run your personalized report
Premium turns your target life into a required-income number, then tests it against these paths for salary-only gap, ownership upside, call burden, and geography. Evidence depth and confidence stay visible inside every report.